Friday, 19 Oct 2018

Biologic/Novel Rx

Datesort ascending Type Title Save
24 Jul 2017 Social Samsung Bioepis launches U.S. sales of Remicade biosmiliar- Renflexis https://t.co/emo6Te0yyW
24 Jul 2017 News Rheumatologists and Patients Concerns over Biosimilars - RheumNow “Live Vote” Results
20 Jul 2017 Social 7 pts w/ Active Refractory Takayasu arteritis Tx w/ RTX w/ mixed results - 3 achieved remission but 4 failed to resp https://t.co/rXSNc6qpTn
13 Jun 2017 News Supreme Court Decision Favors Earlier Biosimilar Adoption
07 Jun 2017 News Upadacitinib Effective in Rheumatoid Arthritis
05 Jun 2017 News Biosimilar Reports – May 2017
25 May 2017 Social RT @RWCSmtg: NOR-SWITCH trial suggests Remicade Can Be Substituted for Less Expensive Biosimilar CT-P13 https://t.co/oTpLD9Qymf #psoriasis…
24 May 2017 News Anti-IL-5 Success in Eosinophilic Granulomatosis with Polyangiitis
23 May 2017 Social Kevzara-the 2nd IL-6 inhibitor approved for use in RA; priced at $39K, 30% below competition https://t.co/mzIOOhEnMe https://t.co/2U3J2sskum
23 May 2017 Social FDA approves Actemra as1st approved drug to treat Giant Cell Arteritis. See RheumNow report. https://t.co/73UieZpbn1 https://t.co/HjUzi0H6OL
23 May 2017 News Actemra - First FDA Approved Drug for Giant Cell Arteritis
22 May 2017 Social @naseema22537544 @DrSimply The new updated PI says its to be given with a tapering course of steroids. https://t.co/SCaiX1FDQx
18 May 2017 Social RT @DrPetryna: @RheumNow could ustekinumab potentially be used in treatment of refractory GCA? Evidence suggests it might https://t.co/Ydr0…
15 May 2017 Social In #Crohns disease Tofacitinib fails to maintain remission in randomized W/D, results of 2 Placebo RCT. https://t.co/9KXQxdq9kw
12 May 2017 Social Uptacitinib (Abbvie Jak 1 inhibitor) shows efficacy in Crohns dz (CELESTE RCTl) w/ remission rates at 6 &24 mg bid https://t.co/ssZT2D6nWk
10 May 2017 Social Responses to Orencia may be dependent on baseline memory B cells (CD38+ CD27+) https://t.co/zro040Y54W
07 May 2017 Social FDA has accepted Sanofi/Regenerons resubmitted BLA for Sarilumab (IL-6 inhib) for RA w/ PFUFA action date 5/22/17 https://t.co/F9txx9QwLz
05 May 2017 Social Japan Study shows 8mg IV Actemra can be escalated to q3 wks IV or reduced to q5 wks IV according to q4wk response https://t.co/rLn6aJowry
04 May 2017 News Tofacitinib Effective in Ulcerative Colitis
04 May 2017 Social Pfizer submitted tofacitinib NDA to FDA for psoriatic arthritis. FDA prev denied the NDA for psoriasis w/ CR letter. https://t.co/bDmnc8QF3c